Skip to content

Definium Therapeutics

US · DFTX #2132 by market cap Listed 1970
28.34 -1.14 -3.87%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 18 in the most recent period (2026/Q3).
  • Total institutional ownership rose 5.6 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
93.14% +5.56pp
Institutions
435 +18
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund62.74%
Hedge Fund20.81%
VC/PE Fund4.78%
Public Company2.32%
Individual/Insider1.21%
Endowment Fund0.67%
Insurance Company0.64%
Private Company0.47%
Family Office/Trust0.35%
Government Pension Fund0.30%
Other6.01%

Top holders as of 2026-09-30

BlackRock 8.60% · 11.77M sh
Capital Research 8.21% · 11.24M sh
FMR 6.59% · 9.02M sh
Avoro Capital Advisors LLC 5.25% · 7.19M sh
Driehaus Capital Management LLC 5.00% · 6.85M sh
Janus Henderson Group plc 4.10% · 5.62M sh
T. Rowe Price Group, Inc. 3.40% · 4.65M sh
Geode Capital Management, LLC 2.66% · 3.64M sh
State Street Global Advisors 2.46% · 3.30M sh
Octagon Capital Advisors LP 2.15% · 2.95M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 36 buys · 14 sells

NameRoleStake
Daniel Karlin Chief Medical Officer 0.42%
Robert Barrow Chief Executive Officer 0.32%
Matthew Wiley Chief Commercial Officer 0.27%
Brandi Roberts Chief Financial Officer 0.19%
Mark Sullivan Chief Legal Officer 0.19%
Schond Greenway Former Chief Financial Officer 0.02%
Roger Crystal Independent Director 0.01%
Suzanne Bruhn Independent Director 0.01%
Carol Vallone Independent Chairperson 0.01%
Andreas Krebs Independent Vice Chairperson 0.01%
David Gryska Independent Director 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-24 Mark Sullivan Chief Legal Officer Automatic Disposition -14,051 $36.57
2026-09-24 Brandi Roberts Chief Financial Officer Automatic Disposition -3,377 $36.57
2026-09-24 Matthew Wiley Chief Commercial Officer Automatic Disposition -3,097 $36.57
2026-09-24 Robert Barrow Chief Executive Officer Automatic Disposition -31,550 $36.57
2026-09-24 Daniel Karlin Chief Medical Officer Automatic Disposition -10,853 $36.57
2026-09-17 Carol Vallone Independent Chairperson Derivative Exercise and Retained +1,086 $35.52
2026-09-17 Andreas Krebs Independent Vice Chairperson Derivative Exercise and Retained +1,629 $35.52
2026-09-13 Mark Sullivan Chief Legal Officer Other Acquisition +125,000 --
2026-09-13 Brandi Roberts Chief Financial Officer Other Acquisition +125,000 --
2026-09-13 Matthew Wiley Chief Commercial Officer Other Acquisition +125,000 --
2026-09-13 Robert Barrow Chief Executive Officer Other Acquisition +750,000 --
2026-09-13 Daniel Karlin Chief Medical Officer Other Acquisition +200,000 --
2026-09-02 Robert Barrow Chief Executive Officer Automatic Disposition -19,023 $37.94
2026-09-01 Robert Barrow Chief Executive Officer Other Acquisition +40,000 --
2026-08-11 Mark Sullivan Chief Legal Officer Other Acquisition +62,500 --
2026-08-11 Brandi Roberts Chief Financial Officer Other Acquisition +62,500 --
2026-08-11 Matthew Wiley Chief Commercial Officer Other Acquisition +62,500 --
2026-08-11 Robert Barrow Chief Executive Officer Other Acquisition +375,000 --
2026-08-11 Daniel Karlin Chief Medical Officer Other Acquisition +100,000 --
2026-06-24 Mark Sullivan Chief Legal Officer Automatic Disposition -13,008 $45.03

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:39 · For reference only, not investment advice and not tailored to your situation.

Definium Therapeutics discussion 0 comments

Add a comment